[HTML][HTML] Burden of post-COVID-19 syndrome and implications for healthcare service planning: A population-based cohort study
…, HE Aschmann, A Domenghino, JS Fehr… - PloS one, 2021 - journals.plos.org
Background Longer-term consequences after SARS-CoV-2 infection are becoming an
important burden to societies and healthcare systems. Data on post-COVID-19 syndrome in the …
important burden to societies and healthcare systems. Data on post-COVID-19 syndrome in the …
Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label …
…, A Antinori, I Dumitru, V Pokrovskiy, J Fehr… - The Lancet, 2014 - thelancet.com
Background Dolutegravir has been shown to be non-inferior to an integrase inhibitor and
superior to a non-nucleoside reverse transcriptase inhibitor (NNRTI). In FLAMINGO, we …
superior to a non-nucleoside reverse transcriptase inhibitor (NNRTI). In FLAMINGO, we …
Mycobacterium tuberculosis transmission in a country with low tuberculosis incidence: role of immigration and HIV infection
…, M Zwahlen, H Furrer, HH Siegrist, J Fehr… - Journal of clinical …, 2012 - Am Soc Microbiol
Immigrants from high-burden countries and HIV-coinfected individuals are risk groups for
tuberculosis (TB) in countries with low TB incidence. Therefore, we studied their role in …
tuberculosis (TB) in countries with low TB incidence. Therefore, we studied their role in …
Infections With the Tick-Borne Bacterium “Candidatus Neoehrlichia mikurensis” Mimic Noninfectious Conditions in Patients With B Cell Malignancies or Autoimmune …
…, E Trysberg, M Stenson, J Fehr… - Clinical Infectious …, 2014 - academic.oup.com
We present a comprehensive study of a new infectious disease in immune compromised
patients, neoehrlichiosis. The clinical picture of the disease can be misleading because the …
patients, neoehrlichiosis. The clinical picture of the disease can be misleading because the …
Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis‐4 score and aspartate …
…, D Braun, B Seifert, A Moncsek, J Fehr… - Liver …, 2017 - Wiley Online Library
Background Novel direct antiviral agents ( DAA ) targeting hepatitis C virus ( HCV ) have
revolutionized the treatment of chronic hepatitis C infection ( CHC ). Rates of sustained …
revolutionized the treatment of chronic hepatitis C infection ( CHC ). Rates of sustained …
Recovery and symptom trajectories up to two years after SARS-CoV-2 infection: population based, longitudinal cohort study
…, A Domenghino, HE Aschmann, A Frei, JS Fehr… - bmj, 2023 - bmj.com
Objective To evaluate longer term symptoms and health outcomes associated with post-covid-19
condition within a cohort of individuals with a SARS-CoV-2 infection. Design …
condition within a cohort of individuals with a SARS-CoV-2 infection. Design …
A high-throughput cell-and virus-free assay shows reduced neutralization of SARS-CoV-2 variants by COVID-19 convalescent plasma
…, V Cagno, SG Nusslé, V D'Acremont, J Fehr… - Science Translational …, 2021 - science.org
The detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–specific
antibodies in the serum of an individual indicates previous infection or vaccination. However, …
antibodies in the serum of an individual indicates previous infection or vaccination. However, …
Clustering and longitudinal change in SARS-CoV-2 seroprevalence in school children in the canton of Zurich, Switzerland: prospective cohort study of 55 schools
…, M Schanz, M Schwarzmueller, A Trkola, J Fehr… - bmj, 2021 - bmj.com
Objectives To examine longitudinal changes in severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) seroprevalence and to determine the clustering of children who were …
2 (SARS-CoV-2) seroprevalence and to determine the clustering of children who were …
Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1–infected patients: week …
…, K Arastéh, G Moyle, G Rizzardini, J Fehr… - The Journal of …, 2013 - academic.oup.com
Background. Cobicistat (COBI) is a pharmacoenhancer with no antiretroviral activity in vitro.
Methods. An international, randomized, double-blind, double-dummy, active-controlled trial …
Methods. An international, randomized, double-blind, double-dummy, active-controlled trial …
Effect of mutation and genetic background on drug resistance in Mycobacterium tuberculosis
…, HH Siegrist, H Furrer, A Calmy, J Fehr… - Antimicrobial agents …, 2012 - Am Soc Microbiol
Bacterial factors may contribute to the global emergence and spread of drug-resistant
tuberculosis (TB). Only a few studies have reported on the interactions between different bacterial …
tuberculosis (TB). Only a few studies have reported on the interactions between different bacterial …